Article Details
Retrieved on: 2024-07-23 16:00:05
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
AstraZeneca secures exclusive option for Pinetree's EGFR degrader, with potential $500M+ deal value. Promising preclinical results in resistant ...
Article found on: www.stocktitan.net
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here